PDS Interest Income vs Other Operating Expenses Analysis
PDSB Stock | USD 1.64 0.03 1.80% |
PDS Biotechnology financial indicator trend analysis is much more than just breaking down PDS Biotechnology Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PDS Biotechnology Corp is a good investment. Please check the relationship between PDS Biotechnology Interest Income and its Other Operating Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Interest Income vs Other Operating Expenses
Interest Income vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PDS Biotechnology Corp Interest Income account and Other Operating Expenses. At this time, the significance of the direction appears to have weak relationship.
The correlation between PDS Biotechnology's Interest Income and Other Operating Expenses is 0.3. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of PDS Biotechnology Corp, assuming nothing else is changed. The correlation between historical values of PDS Biotechnology's Interest Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of PDS Biotechnology Corp are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Interest Income i.e., PDS Biotechnology's Interest Income and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.3 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PDS Biotechnology Corp. It is also known as PDS Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from PDS Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PDS Biotechnology Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At present, PDS Biotechnology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 309.2 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.3K | 1.3M | 4.2M | 4.4M | Depreciation And Amortization | 246.4K | 49.1K | 57.3K | 54.5K |
PDS Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
PDS Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PDS Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.5M | 30.9M | 67.2M | 77.0M | 59.4M | 64.9M | |
Other Current Liab | 1.6M | 1.7M | 2.2M | 8.3M | 2.4M | 3.7M | |
Total Current Liabilities | 2.8M | 3.3M | 3.8M | 9.8M | 13.6M | 7.3M | |
Total Stockholder Equity | 11.7M | 27.1M | 63.2M | 44.0M | 26.1M | 43.3M | |
Property Plant And Equipment Net | 21.1K | 553.1K | 357.7K | 527.5K | 335.0K | 318.3K | |
Net Debt | (12.2M) | (28.2M) | (64.8M) | (50.3M) | (32.7M) | (34.3M) | |
Retained Earnings | (28.9M) | (43.8M) | (60.7M) | (101.6M) | (144.5M) | (137.3M) | |
Accounts Payable | 1.2M | 1.4M | 1.3M | 1.2M | 7.0M | 7.3M | |
Cash | 12.2M | 28.8M | 65.2M | 73.8M | 56.6M | 61.8M | |
Non Current Assets Total | 21.1K | 553.1K | 357.7K | 527.5K | 335.0K | 318.3K | |
Cash And Short Term Investments | 12.2M | 28.8M | 65.2M | 73.8M | 56.6M | 61.8M | |
Common Stock Total Equity | 10.6K | 1.7K | 7.3K | 10.0K | 11.4K | 7.5K | |
Common Stock Shares Outstanding | 4.9M | 16.7M | 25.6M | 28.6M | 31.0M | 32.5M | |
Liabilities And Stockholders Equity | 14.5M | 30.9M | 67.2M | 77.0M | 59.4M | 64.9M | |
Non Current Liabilities Total | 1.2M | 490.4K | 231.4K | 23.2M | 19.6M | 10.4M | |
Other Current Assets | 2.3M | 1.5M | 1.6M | 2.7M | 2.5M | 1.6M | |
Other Stockholder Equity | 40.6M | 70.9M | 123.9M | 145.6M | 170.6M | 136.7M | |
Total Liab | 2.8M | 3.8M | 4.0M | 33.0M | 33.3M | 34.9M | |
Property Plant And Equipment Gross | 21.1K | 553.1K | 357.7K | 527.5K | 467.8K | 444.4K | |
Total Current Assets | 14.5M | 30.3M | 66.8M | 76.5M | 59.1M | 63.4M | |
Common Stock | 1.7K | 7.3K | 9.4K | 10.0K | 10.9K | 8.1K | |
Other Assets | 11.5K | 12.8K | 547.7K | 1.0 | 1.15 | 1.09 | |
Capital Surpluse | 222.6M | 40.6M | 70.9M | 145.6M | 131.0M | 122.2M | |
Property Plant Equipment | 21.1K | 553.1K | 357.7K | 527.5K | 474.8K | 438.1K | |
Net Tangible Assets | 11.7M | 27.1M | 63.2M | 44.0M | 50.6M | 53.1M | |
Net Invested Capital | 11.7M | 27.1M | 63.2M | 67.0M | 49.8M | 52.1M | |
Net Working Capital | 11.7M | 27.1M | 63.1M | 66.7M | 45.4M | 50.2M | |
Capital Stock | 1.7K | 7.3K | 9.4K | 10.0K | 10.9K | 9.2K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.